SPDR S&P Biotech

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Madrigal Pharmaceuticals Reports Q1 2026 Net Loss Widens to $94.39M Despite Strong Rezdiffra Revenue Amidst Uncertainty

Bank of America Analyst Maintains Buy Rating on Travere Therapeutics with $50 Target Price

Travere Therapeutics Completes $525 Million Convertible Note Issuance for Refinancing and Operations

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Arrowhead Advances RNAi Pipeline, REDEMPLO Launches with Over 400 Prescriptions in First Quarter

Travere Therapeutics Receives 'Modest Buy' Consensus Rating from Thirteen Analysts

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Travere Therapeutics issues convertible notes and repurchases existing convertible notes

Celldyne Announces New Data Release for MYQORZO® at the 2026 European Heart Failure Conference

Cytokinetics Announces Aficamten Superior to Metoprolol in Phase III Study

Madrigal's Rezdiffra Strong Sales, ZSP1601 Shows Potential in Anti-Fibrotic Therapy

Arrowhead Pharmaceuticals Announces Q2 2026 Earnings Report with Increased Net Loss

Arrowhead Pharmaceuticals Q2 Revenue Falls Short of Estimates

ArrowHead Pharma released FY2026 Semi-Annual earnings on May 7 During-Market (EST), actual revenue USD 337.77 M, actual EPS USD -0.73

ArrowHead Pharma released FY2026 Q2 earnings on May 7 During-Market EST, actual revenue USD 73.74 M (forecast USD 71.71 M), actual EPS USD -0.9319 (forecast USD -1.115)

Travere Therapeutics Insider Sells Shares, Raises Short-Term Sell Pressure Concerns

Cytokinetics Prices Expanded Public Offering, Expected to Raise $700 Million

Meiwu Tech

Amesite

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Co-Diagnostics

MetaVia

Phoenix Asia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Gen Digital - Rights

Pinned News

置顶新闻

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

HOTH

LABU

Hoth Therapeutics Inc. plans to rebrand as Rocket One Inc. to focus on AI semiconductor technologies and ultra-low-power AI computing. The board unanimously approved this strategic shift, which includes securing exclusive rights to technologies from Virginia Commonwealth University. The company will maintain its biotechnology operations while addressing AI infrastructure challenges. Hoth's shares fell 9.69% to $0.55 in premarket trading, reflecting a 20.9% decline over the past month.

benzinga_article

Hoth Therapeutics

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

S&P 500

UCBJY

IBBQ

SBIO

ARKG

UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating active psoriatic arthritis. At week 16, 49.1% of bimekizumab patients achieved ACR50 compared to 38.4% for risankizumab. Early improvements were noted as early as week 4. No new safety concerns were reported, although mild to moderate candida infections were more common with bimekizumab.

PharmaTimes

UCB S.A.

United Community Banks

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares US Pharma

VG Health

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

AMIX

A revolutionary technology has been developed that allows for minimally invasive transvascular access to nerve targets and tissues. This innovative method enables access through and beyond the lumen wall, providing a less invasive approach for procedures. This breakthrough is set to significantly improve treatment options for patients, with a success rate of over 90% in initial clinical trials. This technology is expected to benefit a wide range of medical fields and has the potential to transform minimally invasive procedures globally.

Unusual Whales

Autonomix Medical

iShares US Medical Devices

SPDR S&P Health Equip

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

IBRX

ImmunityBio presented analyses at the AUA 2026 meeting showing that ANKTIVA plus BCG resulted in higher complete response rates and longer-lasting benefits compared to nadofaragene in BCG-unresponsive non-muscle invasive bladder cancer. The combination also demonstrated a cleaner safety profile against TAR-200. However, the data were derived from cross-trial comparisons, which may affect interpretation by investors and clinicians.

PUBT

ImmunityBio

ImmunityBio reports higher complete response rates for ANKTIVA plus BCG in AUA analysis

Nexalin has completed the acquisition of the PONM digital health platform from GreenLight Ventures for $1.3 million, paid in Nexalin stock. The deal includes an exclusive license for AI-enabled software features and supports a planned FDA trial for HALO Clarity. GreenLight will also become an equity holder and provide ongoing support.

Nexalin Tech

NEXALIN TECHNOLOGY INC C/WTS 22/09/25(TO PUR COM)

Nexalin closes acquisition of PONM digital health platform for USD 1.3 million

RNXT

RenovoRx (RNXT) reported a record Q1 2026 revenue of $563,000, a 136% increase from Q4 2025. The company has expanded its commercial cancer centers to 16 and aims for 36 by year-end. Management reiterated a 2026 revenue target of $3-4 million, supported by a strong pipeline and cash position of $12.4 million. The TIGER-PACT Phase III trial is nearing completion, with 93% of patient enrollment achieved. Operating expenses are expected to remain stable, facilitating further revenue growth.

Motley Fool

RenovoRx

RenovoRx (RNXT) Q1 2026 Earnings Transcript

ENTA

Enanta Pharmaceuticals Inc. (ENTA) is showcasing its investigational programs, Zelicapavir and EPS-3903, at the ATS International Conference. Zelicapavir is an oral antiviral targeting the N-protein for treating respiratory syncytial virus, disrupting viral replication directly.

rttnews

Enanta Pharma

Enanta Pharma's RSV Bet And Immunology Ambitions

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

Market Beat

West Pharmaceutical

Arcadian Asset

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

EDSA

Edesa Biotech will present new clinical data on paridiprubart for acute kidney injury at the 63rd European Renal Association Congress in Glasgow from June 3-6, 2026. The analysis indicates a significant reduction in mortality among patients with acute kidney injury, suggesting a potential targeted therapy. An oral presentation is scheduled for June 5, 2026.

Edesa Biotech

Edesa Biotech presents new paridiprubart acute kidney injury data at ERA Congress

BAYN

BAYRY

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer AG

Bayer

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

STRO

Duality Biotherapeutics has announced a share buyback plan of up to USD 40 million, funded from internal resources, with shares to be held as treasury stock. Chairman and CEO Zhu Zhongyuan will also purchase up to USD 5 million in shares using personal funds. The announcement was made on May 19, 2026.

Sutro Biopharma

DUALITYBIO-B

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

Duality Biotherapeutics plans share buyback of up to US$40 million

SPDR S&P Biotech(XBI.US)